
Cipla Ltd. share price
NSE: CIPLA · Healthcare
₹1,394.50 +0.19%
Closing price data, updated 17 Nov 2026. 52-week range: -9.4% from high, +19.6% above low.
Price₹1,394.50
Market cap₹1,12,658 Cr
P/E38.9
P/B3.18
ROE11.8%
ROCE14.9%
Debt / equity0.02
Dividend yield0.00%
EPS₹35.86
Book value₹438.13
Operating margin17.5%
Dipscan score51 / 100
Share: WhatsAppX / TwitterTelegram
Cipla Ltd. shareholding pattern
As of Sep 2026: Promoters 29.21%, FIIs 20.25%, DIIs 34.94%, Government 0.00%, Public 13.41%, Others 2.19%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 29.21% | 29.21% | 29.21% | 29.21% | 29.21% | 29.19% |
| FIIs | 20.25% | 20.21% | 22.56% | 23.93% | 24.55% | 25.25% |
| DIIs | 34.94% | 34.63% | 31.97% | 30.72% | 30.25% | 29.26% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 13.41% | 13.74% | 13.98% | 13.84% | 13.82% | 14.10% |
| Others | 2.19% | 2.20% | 2.28% | 2.29% | 2.16% | 2.20% |
| No. of Shareholders | 562,798 | 578,679 | 584,217 | 540,521 | 534,587 | 549,655 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| +0.19% | -1.17% | +6.08% | -4.41% | -2.94% | -7.95% |
Growth
| Sales growth, 3 years | +7.2% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +11.4% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | – |
| Latest quarter profit vs last year | – |
Strengths and weaknesses
Strengths
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 25.7%
Weaknesses
- The company has delivered a poor sales growth of 8.01% over past five years.
- Promoter holding has decreased over last 3 years: -4.26%
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Mankind Pharma Ltd. | ₹2,626.60 | ₹1,08,490 Cr | 48.4 | 12.5% | +18.3% |
Frequently asked questions
What is the share price of Cipla Ltd.?
Cipla Ltd. (CIPLA) last closed at ₹1,394.50 (+0.19% on the day).
What is the market cap of Cipla Ltd.?
About ₹1,12,658 Cr.
What is the P/E ratio of Cipla Ltd.?
The price-to-earnings ratio is 38.9, and return on equity is 11.8%.
Figures are calculated from company results and exchange prices and are for information only.